Dr. Sarah Polfliet M.D.

Treatments

• Adult Psychiatry

Fellowships

• Forensic Psychiatry at the University of California, San Francisco

Professional Society Memberships

• American Medical Association, American Psychiatric Association

Articles and Publications

•  

  A National Analysis of Medical Licensure Applications.  Published in the Journal of the  American Academy of Psychiatry and the Law, Volume 36, Number 3, 2008.

   

   

  Application of the Standards for Diminished Mental Capacity or for the Acceptance-of-Responsibility in Sentencing Mentally Ill Persons.  American Academy of Psychiatry and the Law Journal, Volume 35, Number 2, 2007.

   

   

  Complementary Treatments in Psychiatry: Herbs and Supplements. Newsletter for the Association of Women Psychiatrists, pgs 4-7, Winter 2005.

Areas of research

• Apr 2015-Present       Sub-Investigator: A Randomized, Double-Blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression. Sustenance of Esketamine Treatment Response with Repeated Doses at Intervals Determined by Symptom Severity) (Sustain -1)

   

  Apr 2015-Present       Sub-Investigator: A Randomized, Double-Blind, Multicenter, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects with Treatment-Resistant Depression (Transform-2)

   

  Jun 2015-Present       Sub-Investigator: A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment with Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics (R092670SCH3013), Janssen Scientific Affairs

   

  Feb 2015-Oct 2015    Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia (SD-809-C-23), Auspex Pharmaceuticals        

   

  May 2012-Sep 2015   Sub-Investigator: A Multicenter, Open-Label, Flexible Dose Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects with Bipolar I Disorder (D1050308), Sunovion Pharmaceuticals

   

  May 2012-Jun 2014    Sub-Investigator: A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia (R092670-PSY3012), Janssen Pharmaceuticals

   

  Mar 2012-Nov 2013    Sub-Investigator: A Multicenter, Open-label Study to Assess Hospitalization Rates in Adults Subjects with Schizophrenia Treated Prospectively     for 6 Months with Aripiprazole IM Depot Compared with 6-Month Retrospective Treatment with Oral Antipsychotics in a Naturalistic Community Setting in the United States (31-11-283), Otsuka Pharmaceuticals

   

  Jul 2011-Present        Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or     Divalproex for the Prevention of Recurrence in Subjects with Bipolar Disorder (D1050296), Sunovion Pharmaceuticals 

   

Dr. Sarah Polfliet M.D.'s Practice location